These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17659484)

  • 1. Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.
    van Poelje PD; Dang Q; Erion MD
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):430-7. PubMed ID: 17659484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
    van Poelje PD; Potter SC; Erion MD
    Handb Exp Pharmacol; 2011; (203):279-301. PubMed ID: 21484576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
    Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
    J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase].
    Li ZM; Bie JB; Song HR; Xu BL
    Yao Xue Xue Bao; 2011 Nov; 46(11):1291-300. PubMed ID: 22260018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
    Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
    J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
    Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
    Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
    Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
    J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.
    Kaur R; Dahiya L; Kumar M
    Eur J Med Chem; 2017 Dec; 141():473-505. PubMed ID: 29055870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
    Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
    Erion MD; van Poelje PD; Dang Q; Kasibhatla SR; Potter SC; Reddy MR; Reddy KR; Jiang T; Lipscomb WN
    Proc Natl Acad Sci U S A; 2005 May; 102(22):7970-5. PubMed ID: 15911772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent and orally active tricyclic-based FBPase inhibitors.
    Tsukada T; Kanno O; Yamane T; Tanaka J; Yoshida T; Okuno A; Shiiki T; Takahashi M; Nishi T
    Bioorg Med Chem; 2010 Jul; 18(14):5346-51. PubMed ID: 20542703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New hepatic targets for glycaemic control in diabetes.
    Agius L
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
    Visinoni S; Fam BC; Blair A; Rantzau C; Lamont BJ; Bouwman R; Watt MJ; Proietto J; Favaloro JM; Andrikopoulos S
    Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1132-41. PubMed ID: 18780768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a QM/MM-based FEP method to evaluate the anomalous hydration behavior of simple alkyl amines and amides: application to the design of FBPase inhibitors for the treatment of type-2 diabetes.
    Reddy MR; Singh UC; Erion MD
    J Am Chem Soc; 2011 Jun; 133(21):8059-61. PubMed ID: 21545145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
    Hebeisen P; Haap W; Kuhn B; Mohr P; Wessel HP; Zutter U; Kirchner S; Ruf A; Benz J; Joseph C; Alvarez-Sánchez R; Gubler M; Schott B; Benardeau A; Tozzo E; Kitas E
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3237-42. PubMed ID: 21550236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
    Xu YX; Huang YY; Song RR; Ren YL; Chen X; Zhang C; Mao F; Li XK; Zhu J; Ni SS; Wan J; Li J
    Eur J Med Chem; 2020 Oct; 203():112500. PubMed ID: 32711108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
    Bie J; Liu S; Zhou J; Xu B; Shen Z
    Bioorg Med Chem; 2014 Mar; 22(6):1850-62. PubMed ID: 24530031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
    Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
    J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
    Kitas E; Mohr P; Kuhn B; Hebeisen P; Wessel HP; Haap W; Ruf A; Benz J; Joseph C; Huber W; Sanchez RA; Paehler A; Benardeau A; Gubler M; Schott B; Tozzo E
    Bioorg Med Chem Lett; 2010 Jan; 20(2):594-9. PubMed ID: 19969452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.